Subgroup analysis of participants (pts) with HER2 IHC0 in the ASCENT-07 study of sacituzumab govitecan (SG) vs chemotherapy in HR+/ HER2− metastatic breast cancer (mBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yeon Hee Park, Komal L. Jhaveri, Carlos H. Barrios, Giuseppe Curigliano, Hiroji Iwata, Javier Cortes, Delphine Loirat, Tomás Pascual, Zhimin Shao, Carlos Gallardo, Toshinari Yamashita, Marta Cespedes, Pelin Cinar, Molly Lam, Xuehan Ren, Brittany Fleming, Joyce Kwan, Kevin Punie, Hope S. Rugo
Institutions: Samsung Medical Center, Sungkyunkwan University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Latin American Cooperative Oncology Group (LACOG), University of Milan, European Institute of Oncology, Nagoya City University, Institut Curie, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Fudan University, Fudan University Shanghai Cancer Center, Kanagawa Cancer Center, Hospital Clínico Universitario de Valencia, Gilead Sciences (United States), Ziekenhuis aan de Stroom, City Of Hope National Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162504344
Cites:
Cited by:
Related to: